What did ODYSSEY Outcomes and FOURIER teach us about high-risk patients with diabetes and the relative favorability of their responses to LDL-C lowering with PCSK9 inhibitors?

What did ODYSSEY Outcomes and FOURIER teach us about high-risk patients with diabetes and the relative favorability of their responses to LDL-C lowering with PCSK9 inhibitors?

What did ODYSSEY Outcomes and FOURIER teach us about high-risk patients with diabetes and the relative favorability of their responses to LDL-C lowering with PCSK9 inhibitors? 


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

Associate Head, Division of Cardiology St. Michael’s Hospital